Singapore-based healthtech startup Mesh Bio has raised around $1.8 million in a funding round, media reports said. The funding round for the startup was led by deeptech investor Elev8.vc and SEEDS Capital, the investment arm of Enterprise Singapore. Other investors that also participated in the funding round for Mesh Bio includes Wealth management firm Citrine Capital as well as Singaporean VC firm Tael Partners.
With regard to the funding in Mesh Bio, Aditya Mathur, founder of Elev8.vc told the media, “Rapidly ageing populations across the world deserve far better healthcare. Mesh Bio’s predictive analytics offers a clinically validated technology to detect and support chronic diseases before they even occur.”
Established in 2018 by Andrew Wu (former COO of Clearbridge Biomedics), Arsen Batagov (former bioinformatics scientist), and Melvin Heng (physician and hospital administrator) , Mesh Bio develops clinical decision support analytics and automation solutions for the management of chronic diseases, such as cardiovascular illnesses.
In November, Japan-based medical equipment manufacturer and healthtech startup HeartVoice launched a health programme called ‘Back on Track’ in Singapore. The programme is designed to help its users engage with their own health through regular participation. To launch the programme in Singapore, Omron and HeartVoice are teaming up with local insurer Great Eastern.
In this regard, Daisuke Nozaki, Managing Director of HeartVoice told the media, “Back On Track! users will be also receiving health tips as a reminder to make healthier choices on a daily basis via HeartVoice App. Friendly nudges to stay healthier can make a great behavioral change in the long run.”